VI
PACB icon

Versor Investments’s Pacific Biosciences PACB Stock Holding History

Versor Investments’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-13,400
Closed -$18.4K – 928
2024
Q2 		$18.4K Sell
13,400
-16,379
-55% -$33.1K ﹤0.01% 699
2024
Q1 		$112K Sell
29,779
-35,412
-54% -$207K 0.02% 649
2023
Q4 		$640K Buy
65,191
+8,723
+15% +$71.3K 0.13% 255
2023
Q3 		$472K Buy
+56,468
New +$645K 0.1% 334
2022
Q3 		– Sell
-10,000
Closed -$44K – 906
2022
Q2 		$44K Buy
+10,000
New +$60.8K ﹤0.01% 777
2020
Q1 		– Sell
-3,148,691
Closed -$16.2M – 321
2019
Q4 		$16.2M Sell
3,148,691
-2,223,929
-41% -$11.3M 0.82% 27
2019
Q3 		$27.7M Buy
5,372,620
+989,998
+23% +$5.54M 1.89% 16
2019
Q2 		$26.5M Buy
4,382,622
+1,264,990
+41% +$8.87M 1.77% 21
2019
Q1 		$22.5M Buy
3,117,632
+2,103,200
+207% +$15.2M 2.14% 20
2018
Q4 		$7.51M Buy
+1,014,432
New +$6.43M 1.72% 16

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Versor Investments's PACB Position: Q3 2024 in Review

Versor Investments sold out of Pacific Biosciences (PACB) in Q3 2024, closing a stake of 13,400 shares — an estimated $18.4K sold.

Versor Investments first reported a position in PACB in Q4 2018 and held it in 10 quarters. The position peaked at $27.7M in Q3 2019. 226 funds tracked by Wall St. Rank hold PACB as of Q3 2024.

  • Versor Investments reported no remaining Pacific Biosciences position as of Q3 2024 after selling out during the quarter.
  • Versor Investments sold 13,400 Pacific Biosciences shares in Q3 2024, an estimated $18.4K.
  • Versor Investments first reported a position in Pacific Biosciences in Q4 2018 and held it in 10 quarters.
  • Versor Investments's Pacific Biosciences position peaked at $27.7M in Q3 2019.
  • 226 funds tracked by Wall St. Rank held Pacific Biosciences as of Q3 2024.

Based on Versor Investments's 13F filing for Q3 2024, filed 4 Nov 2024.